Patient Alert Card

PLASIV®
(APIXABAN)

Carry this card with you at ALL time

Show this card to your pharmacist, dentist and any other healthcare professionals that treat you.

INFORMATION FOR PATIENTS

- Take Plasiv® regularly as instructed by your treating physician. If you miss a dose, take it as soon as you remember and continue to follow your dosing schedule.
- Do not stop taking Plasiv® without talking to your doctor, as you are at risk of suffering from a stroke or other complications. (Refer to the insert leaflet).
- Plasiv® helps to thin your blood. However, this may increase your risk of bleeding. (Refer to the insert leaflet).
- Signs and symptoms of bleeding include bruising or bleeding under the skin, black or tar stools, blood in urine, nose-bleed, dizziness, tiredness, paleness or weakness, sudden severe headache, coughing up blood or vomiting blood.
- If the bleeding does not stop on its own, **immediately seek medical attention**.
- If you need surgery, inform your doctor that you are taking Plasiv®.

TO REPORT SIDE EFFECTS

National Pharmacovigilance Center (NPC):
Call Center: 19999
E-mail: npc.drug@sfda.gov.sa
Website: www.sfda.gov.sa/npc

Alrai Pharmaceutical Industries:
Tel: +966 12 2888949 (Ext. 205)
E-mail: PV@alraipharma.com
Website: www.alraipharma.com

"For more information ask the doctor or pharmacist"
"The information provided on this material is for general informational and educational purposes only, and is not meant to be a substitution for advice provided by your doctor or other qualified healthcare professional"

I am under Anticoagulation treatment with Plasiv® (Apixaban) to prevent blood clots

Patients and Healthcare Professionals are asked to report any suspected adverse reactions via the National Reporting System.

INFORMATION FOR HEALTHCARE PROFESSIONALS

- Plasiv® (Apixaban) is an oral Anticoagulant acting by direct selective inhibition of Factor Xa.
- Plasiv® may increase the risk of bleeding. In case of major bleeding events, it should be stopped immediately.
- Treatment with Plasiv® does not require routine monitoring of exposure. A calibrated quantitative Anti-Factor Xa assay may be useful in exceptional situations, e.g., overdose and emergency surgery (Prothrombin Time (PT), International Normalized Ratio (INR) and activated Partial Thromboplastin Time (aPPT) clotting tests are not recommended) – See SPC.

Please complete this section or ask your doctor to do it

Name:_____

Birth Date:_____

Indication:_____

Dose:_____ **mg twice daily**

Doctor's Name:_____

Doctor's Telephone:_____

* For extra copies, please contact Alrai Pharmaceutical Industries at PV@alraipharma.com
* This document is approved by The Executive Directorate of Pharmacovigilance, at SFDA.